Drug Availability Update
Further to DrugAlert Vol 438, HPS Pharmacies wish to give notice that Arrow Pharma are continuing to experience a supply interruption for Septrin® oral liquid as follows:
Septrin® Oral Liquid
Sulfamethoxazole + trimethoprim 200+40mg/5mL
This supply interruption is due to an unexpected increase in demand following the discontinuation of the Bactrim® brand of sulfamethoxazole + trimethoprim oral liquid. Normal supplies are expected to resume in late June 2019.
An internationally registered brand of sulfamethoxazole + trimethoprim oral liquid is now available for supply under Section 19A of the Therapeutic Goods Act 1989. The packaging of this product is in German and French language. The active ingredient in German language ‘sulfamethoxazolum/trimethoprimum’ is equivalent to ‘sulfamethoxazole/trimethoprim’ in English language. Please refer to the Australian product information for Septrin® for further information.
To ensure this product is used correctly, the Australian consumer medicines information for Septrin® should be supplied to patients and carers. Patients should also be instructed to shake the bottle before use, store below 30°C in a dry place, and discard within four weeks of opening.
Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact GlaxoSmithKline Australia on (03) 9413 7200 or your pharmacist at HPS Pharmacies.